SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 160 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,227,823 | -33.6% | 635,525 | -4.4% | 0.00% | -33.3% |
| Q2 2023 | $13,907,294 | +10.7% | 664,467 | +11.7% | 0.00% | +50.0% |
| Q1 2023 | $12,564,794 | -10.1% | 594,924 | +8.3% | 0.00% | -33.3% |
| Q4 2022 | $13,974,366 | +15.4% | 549,091 | +9.0% | 0.00% | 0.0% |
| Q3 2022 | $12,111,000 | +29.0% | 503,962 | +3.3% | 0.00% | +50.0% |
| Q2 2022 | $9,387,000 | +11.1% | 487,913 | +0.3% | 0.00% | +100.0% |
| Q1 2022 | $8,450,000 | -14.9% | 486,228 | +7.2% | 0.00% | -50.0% |
| Q4 2021 | $9,931,000 | +13.4% | 453,676 | -1.0% | 0.00% | 0.0% |
| Q3 2021 | $8,756,000 | +11.1% | 458,176 | -0.2% | 0.00% | +100.0% |
| Q2 2021 | $7,879,000 | -3.6% | 458,937 | +25.6% | 0.00% | -50.0% |
| Q1 2021 | $8,172,000 | +5.6% | 365,486 | +5.1% | 0.00% | 0.0% |
| Q4 2020 | $7,735,000 | +53.7% | 347,774 | +2.0% | 0.00% | +100.0% |
| Q3 2020 | $5,031,000 | -4.3% | 340,910 | -3.9% | 0.00% | 0.0% |
| Q2 2020 | $5,257,000 | +73.8% | 354,749 | +28.7% | 0.00% | 0.0% |
| Q1 2020 | $3,024,000 | +42.6% | 275,615 | +14.1% | 0.00% | – |
| Q4 2019 | $2,121,000 | +16.5% | 241,549 | -0.9% | 0.00% | – |
| Q3 2019 | $1,820,000 | +3.9% | 243,713 | +29.6% | 0.00% | – |
| Q2 2019 | $1,751,000 | +88.9% | 188,082 | +6.5% | 0.00% | – |
| Q1 2019 | $927,000 | +18.7% | 176,612 | +0.6% | 0.00% | – |
| Q4 2018 | $781,000 | -44.1% | 175,492 | +1.6% | 0.00% | – |
| Q3 2018 | $1,396,000 | +13.7% | 172,802 | -1.2% | 0.00% | – |
| Q2 2018 | $1,228,000 | -40.0% | 174,877 | +21.7% | 0.00% | -100.0% |
| Q1 2018 | $2,046,000 | +51.7% | 143,731 | -6.7% | 0.00% | – |
| Q4 2017 | $1,349,000 | -9.5% | 154,001 | +21.0% | 0.00% | – |
| Q3 2017 | $1,490,000 | -18.1% | 127,277 | -2.2% | 0.00% | -100.0% |
| Q2 2017 | $1,819,000 | +98.4% | 130,196 | +94.7% | 0.00% | – |
| Q1 2017 | $917,000 | +112.8% | 66,860 | +11.2% | 0.00% | – |
| Q4 2016 | $431,000 | -46.3% | 60,102 | +13.5% | 0.00% | – |
| Q3 2016 | $802,000 | +62.0% | 52,951 | +5.4% | 0.00% | – |
| Q2 2016 | $495,000 | – | 50,215 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |